Training program in cancer pharmacology
Training program in cancer pharmacology
批准号:
8535614
负责人:
Ian Alexander Blair
金额:
$50.49万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-24 至 2014-11-30
关键词:
AreaB-LymphocytesBackBiological MarkersBiological ModelsCancer EtiologyCancer PatientCellsClinicalClinical PharmacologyClinical ResearchClinical TrialsClinical and Translational Science AwardsCommunitiesDevelopmentDisciplineDoctor of PhilosophyDoseEducationEducational CurriculumEnvironmentEpidemiologyFacultyFundingFunding OpportunitiesGoalsGrantHematologyHumanIndividualInstitutesInstitutionInstitutional National Research Service AwardInterdisciplinary StudyLaboratoriesLeadLeadershipLearningMalignant NeoplasmsMaster&aposs DegreeMeasuresMedicineMentorsMethodologyMolecularPediatric HospitalsPennsylvaniaPharmaceutical ChemistryPharmaceutical PreparationsPharmacogeneticsPhase I Clinical TrialsPhiladelphiaPlayPostdoctoral FellowProcessQualifyingResearchResearch PersonnelResearch TrainingResourcesRoleScientistSignal TransductionStudentsTestingTherapeuticTherapeutic AgentsTimeTrainingTraining Program for Cancer Prevention and Control Scientists (R25)Training ProgramsTraining and EducationTranslational ResearchTranslationsUniversitiesUpdateValidationWorkanticancer researchbasecancer cellcancer pharmacologycareercareer developmentchemotherapeutic agentdesignexperiencefrontierinterdisciplinary approachmeetingsmultidisciplinarynext generationnovel therapeuticsoncologypatient populationpre-doctoralprogramssmall moleculetranslational medicine
中文摘要
描述(由申请人提供):跨学科癌症药理学培训项目的目的是继续为7名博士生和3名博士后提供宾夕法尼亚大学在发展本项目之前不存在的培训环境。Drs。Blair(项目主任)、Lee(项目联合主任)和Penning(项目联合主任)将为癌症教育和职业发展项目(CECDP)的持续发展提供所需的持续领导。在未来十年中,癌症治疗的重大进展将来自多学科方法,以了解恶性细胞在分子水平上如何工作,并设计新的治疗药物来破坏这些过程。因此,CECDP将有助于填补目前有资格开发下一代化疗药物的个体的不足。该项目的最终目标是提供从实验室到床边再回来的癌症药理学培训。具体来说,学员将学习如何使用癌症药理学来确定新的靶点,如何合成小分子并针对这些靶点进行测试,如何在I期试验中使用它们,如何将这些研究发展为完整的临床试验,以及如何利用流行病学和药物遗传学来评估疗效并导致新靶点的发现。受训者还将接受具体培训,学习如何将药物效应的定量测量从模型系统的概念证明投射到人体剂量的合理选择中。这些目标将通过CECDP提供的课程和跨学科研究经验来实现。在宾夕法尼亚大学生物医学研究生研究的9个研究生小组中,有8个小组拥有30名具有不同互补专业知识的教师导师。导师在CECDP中分为三个子项目:A.癌症病因学和治疗学。B.细胞与分子肿瘤药理学。C.临床肿瘤药理学。每个学员将有两个研究导师,分别隶属于两个不同的子项目。作为癌症研究人员,导师们有着非常出色的成就记录,并且通过与nci资助的临床项目的联系,他们可以很好地接触到不同的患者群体。此外,其中一位导师是宾夕法尼亚大学翻译医学研究所和临床转化科学奖的主任(加勒特·菲茨杰拉德博士),一位是临床药理学和治疗学部门主任,以及费城儿童医院临床和转化研究办公室主任(彼得·亚当森博士)。这两位导师都有专注于转化疗法的研究项目,因此他们提供了另一种优秀的培训资源。在转化研究硕士课程(MTR)和新的临床领导由李博士提供的血液/肿瘤部门将提供额外的转化机会。除了传统的博士和博士后研究之外,港铁项目还将提供给学员。癌症药理学CECDP的目标将通过三个具体目标来实现。具体目标1:为癌症药理学领域的学员提供独特的教学经验。具体目标2:为博士生和博士后提供癌症药理学的跨学科研究培训。具体目标3:为博士生和博士后提供转化医学和癌症治疗方面的培训。
英文摘要
DESCRIPTION (provided by applicant): The purpose of the interdisciplinary Cancer Pharmacology training program is to continue providing seven predoctoral students and three postdoctoral fellows with a training environment that did not exist at the University of Pennsylvania prior to the development of the present program. Drs. Blair (Program Director), Lee (Program Co-Director), and Penning (Program Co-Director) will provide the sustained leadership required to continue development of the Cancer Education and Career Development Program (CECDP). Major advances in the treatment of cancer patients in the next decade will result from multidisciplinary approaches in understanding of how malignant cells work at the molecular level and in designing novel therapeutic agents to disrupt these processes. Therefore, the CECDP will help fill the current deficit of individuals qualified to develop the next generation of chemotherapeutic agents. The ultimate goal of the program is to provide training in cancer pharmacology that goes from laboratory to bedside and back again. Specifically, trainees will learn how cancer pharmacology can be used to identify new targets, how small molecules are synthesized and tested against these targets, how they are used in Phase I trials, how these studies are developed into full clinical trials, and how epidemiology and pharmacogenetics can be utilized to assess efficacy and lead to the discovery of new targets. Trainees will also receive specific training in how to project quantitative measures of drug effect from proof of concept in model systems into the rational selection of dosing in humans. These goals will be accomplished through the courses and interdisciplinary research experience that are offered in the CECDP. There are thirty faculty mentors with diverse complementary expertise who belong to eight of the nine graduate groups that are involved in Biomedical Graduate Studies at the University of Pennsylvania. Mentors are grouped into three sub-programs within the CECDP: A. Cancer Etiology and Therapeutics. B. Cell and Molecular Cancer Pharmacology. C. Clinical Cancer Pharmacology. Each trainee will have two research mentors affiliated with two different sub-programs. The mentors have a very strong record of accomplishment as cancer researchers as well as superb access to different patient populations through their association with NCI-funded clinical programs. Furthermore, one of the mentors is Director of the Institute of Translation Medicine and the Clinical Translational Science Award at the University of Pennsylvania (Dr. Garret FitzGerald) and one is Division Chief, Clinical Pharmacology and Therapeutics, and Director of the Office of Clinical and Translational Research at the Children's Hospital of Philadelphia (Dr. Peter Adamson). Both of these mentors have research programs with a focus on translational therapeutics and so they provide another outstanding training resource. The Master's program in Translational Research (MTR) and new clinical leadership provided by Dr. Lee from the Division of Hematology/Oncology will provide additional translational opportunities. The MTR program will be available to trainees in addition to their conventional PhD and postdoctoral studies. Goals of the CECDP in Cancer Pharmacology will be accomplished through three specific aims. Specific Aim 1: To provide unique didactic experiences to trainees in the field of cancer pharmacology. Specific Aim 2: To provide interdisciplinary research training in cancer pharmacology to predoctoral students and postdoctoral fellows. Specific Aim 3: To provide predoctoral and postdoctoral researchers with training in translational medicine and cancer therapeutics.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1371/journal.pone.0050099
发表时间:
2012
期刊:
PloS one
影响因子:
3.7
作者:
[Zhu J, Siclari VA, Liu F, Spatz JM, Chandra A, Divieti Pajevic P, Qin L]
通讯作者:
Qin L
DOI:
10.1158/0008-5472.can-10-2286
发表时间:
2010-12-01
期刊:
Cancer research
影响因子:
11.2
作者:
[Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, Brown EJ]
通讯作者:
Brown EJ
DOI:
10.1016/j.bone.2012.12.013
发表时间:
2013-04
期刊:
BONE
影响因子:
4.1
作者:
[Siclari, Valerie A., Zhu, Ji, Akiyama, Kentaro, Liu, Fei, Zhang, Xianrong, Chandra, Abhishek, Nah, Hyun-Duck, Shi, Songtao, Qin, Ling]
通讯作者:
Qin, Ling
DOI:
10.1038/onc.2012.240
发表时间:
2013-05-02
期刊:
ONCOGENE
影响因子:
8
作者:
[Furcht, C. M., Rojas, A. R. Munoz, Nihalani, D., Lazzara, M. J.]
通讯作者:
Lazzara, M. J.
DOI:
10.1083/jcb.201303110
发表时间:
2013-10-14
期刊:
The Journal of cell biology
影响因子:
--
作者:
[Ochocki JD, Simon MC]
通讯作者:
Simon MC
共 11 条
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
-
批准号:10337249
-
项目类别:
-
资助金额:$47.03万
-
财政年份:2020
-
负责人:Ian Alexander Blair
-
依托单位:
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
-
批准号:10115684
-
项目类别:
-
资助金额:$47.94万
-
财政年份:2020
-
负责人:Ian Alexander Blair
-
依托单位:
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
-
批准号:10565951
-
项目类别:
-
资助金额:$47.03万
-
财政年份:2020
-
负责人:Ian Alexander Blair
-
依托单位:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
-
批准号:10356088
-
项目类别:
-
资助金额:$75.2万
-
财政年份:2020
-
负责人:Ian Alexander Blair
-
依托单位:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
-
批准号:10582596
-
项目类别:
-
资助金额:$81.13万
-
财政年份:2020
-
负责人:Ian Alexander Blair
-
依托单位:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
-
批准号:10117295
-
项目类别:
-
资助金额:$75.4万
-
财政年份:2020
-
负责人:Ian Alexander Blair
-
依托单位:
Asbestos fate, exposure, remediation, and adverse health effects
-
批准号:9530878
-
项目类别:
-
资助金额:$4.95万
-
财政年份:2014
-
负责人:Ian Alexander Blair
-
依托单位:
Asbestos fate, exposure, remediation, and adverse health effects
-
批准号:9041609
-
项目类别:
-
资助金额:$225.31万
-
财政年份:2014
-
负责人:Ian Alexander Blair
-
依托单位:
Asbestos fate, exposure, remediation, and adverse health effects
-
批准号:8651082
-
项目类别:
-
资助金额:$227.78万
-
财政年份:2014
-
负责人:Ian Alexander Blair
-
依托单位:
Development of Breast Cancer Risk Model Based on Estrogen Metabolomics
-
批准号:8550778
-
项目类别:
-
资助金额:$33.58万
-
财政年份:2012
-
负责人:Ian Alexander Blair
-
依托单位:
Core N: MOLECULAR PROFILING
-
批准号:8126787
-
项目类别:
-
资助金额:$31.14万
-
财政年份:2012
-
负责人:Ian Alexander Blair
-
依托单位:
Development of Breast Cancer Risk Model Based on Estrogen Metabolomics
-
批准号:8297591
-
项目类别:
-
资助金额:$44.28万
-
财政年份:2012
-
负责人:Ian Alexander Blair
-
依托单位:
Biomarkers of toxic response to low nicotine cigarette smoke
-
批准号:8259538
-
项目类别:
-
资助金额:$56.09万
-
财政年份:2009
-
负责人:Ian Alexander Blair
-
依托单位:
Biomarkers of toxic response to low nicotine cigarette smoke
-
批准号:7847681
-
项目类别:
-
资助金额:$58.65万
-
财政年份:2009
-
负责人:Ian Alexander Blair
-
依托单位:
Biomarkers of toxic response to low nicotine cigarette smoke
-
批准号:7740487
-
项目类别:
-
资助金额:$57.78万
-
财政年份:2009
-
负责人:Ian Alexander Blair
-
依托单位:
Biomarkers of toxic response to low nicotine cigarette smoke
-
批准号:8193242
-
项目类别:
-
资助金额:$56.21万
-
财政年份:2009
-
负责人:Ian Alexander Blair
-
依托单位:
Molecular mechanisms of DNA damage by PAHs
-
批准号:8104007
-
项目类别:
-
资助金额:$29.25万
-
财政年份:2007
-
负责人:Ian Alexander Blair
-
依托单位:
Exposure and biological response biomarkers of cigarette smoke
-
批准号:7847893
-
项目类别:
-
资助金额:$0.79万
-
财政年份:2007
-
负责人:Ian Alexander Blair
-
依托单位:
Exposure and biological response biomarkers of cigarette smoke
-
批准号:7822322
-
项目类别:
-
资助金额:$2.58万
-
财政年份:2007
-
负责人:Ian Alexander Blair
-
依托单位:
Molecular mechanisms of DNA damage by PAHs
-
批准号:7883299
-
项目类别:
-
资助金额:$30.38万
-
财政年份:2007
-
负责人:Ian Alexander Blair
-
依托单位:
海外基金